Intelligent Multi-omics Diagnosis and Prognosis System for Breast Cancer Based on Femtosecond Laser Multimodal Molecular Imaging

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600126186

Enrollment

Unknown

Registered

2026-06-04

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Intraoperative frozen pathological diagnosis and conventional pathological diagnosis of tissue specimens

Index test:Rapid diagnosis of tissue specimens using a femtosecond laser multimodal molecular imaging platform

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients undergoing biopsy or surgery for breast disease who can provide tissue specimens for pathological examination. This includes patients with both benign breast disease and malignant breast tumors. For patients with malignant breast tumors, there are no restrictions on: * ECOG Performance Status (PS) score * Tumor TNM staging * Tumor molecular subtype; 2. Patients must be age >=18 years of age and provide informed consent (i.e., willingly and voluntarily participate in the project and be able to sign the informed consent form independently).

Exclusion criteria

Exclusion criteria: 1.Patients who refuse to participate in the clinical observational study.

Design outcomes

Primary

Measure	Time frame
False negative rate;Specificit;Area Under the Curve, AUC;False positive rate;Kappa Coefficient;ROC Curve;Sensitivity;	—

Countries

China

Contacts

Public ContactYulei Wang

Maoming People's Hospital

yuleiwang@whu.edu.cn+86 20 83827812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026